Details

Last Funding Type

Debt Financing

Last Funding Money Raised

$100M

Industries

Biopharma,Biotechnology,Health Care,Medical

Founded date

Jan 1, 2017

Number Of Employee

101 - 250

Operating Status

Active

Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). Urovant’s second investigational product candidate, URO-902, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.